StockData
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Boundless Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.31−0.03 (-1.28%)

Close on Oct 19, 2026

Market cap
$51.86M
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q1 FY2026
Ended Mar 31, 2026
May 8, 2026Before market open–$-0.60–
Q4 FY2025
Ended Dec 31, 2025
Mar 9, 2026Before market open–$-0.58–
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025Before market open–$-0.62–
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025Before market open–––
Q1 FY2025
Ended Mar 31, 2025
May 9, 2025Before market open–$-0.71–
Q4 FY2024
Ended Dec 31, 2024
Mar 27, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024After market close–––
Q2 FY2024
Ended Jun 30, 2024
Aug 12, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 13, 2024Before market open–$-12.27–

Press releases

Announcements Boundless Bio filed with the SEC